Sei nella sezione

Review

Clinical Practice 23 Set 2021

The role of tralokinumab in the treatment of atopic dermatitis

Atopic dermatitis (AD) represents the commonest inflammatory skin disorder in the developed world. A staggering one-fifth of the population in those countries is affected by AD. This review summarises the promising efficacy and safety results obtained in patients with moderate-to-severe AD treated with tralokinumab, a new biologic agent for the systemic treatment of the disease

Leggi tutto

DIGITAL HEALTH

Leggi tutto

CLINICAL CASES